The right time to move to an automated manufacturing system like the Cocoon platform: the when, the why, and the how
On demand

The right time to move to an automated manufacturing system like the Cocoon platform: the when, the why, and the how

Thursday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET
The right time to move to an automated manufacturing system like the Cocoon platform: the when, the why, and the how

With the current explosion in the number of cell therapies moving to the clinic, we need to continue to evaluate bioprocessing technology paradigms, and how different workflows progress from early R&D to commercial manufacturing.

Fundamental questions still exist in the debate between using segmented platforms with individual unit operations or utilizing a fully automated platform.

During this webinar, we want to take a deeper look into the process development path. We will start from early process development and how this effects the considerations as we move into the clinic and ultimately, into commercial manufacturing. We will discuss how an automated manufacturing platform like the Cocoon can ease tech transfer when adopted in the early stages of development, and ensure you have a scalable solution from pre-clinical to commercial scale manufacturing. Donna Rill from Triumvira Immunologics will also share her manufacturing experience and explain why Triumvira chose to adopt a closed and automated system prior to entering clinical trials.

Attendees will learn about:

  • Understanding the differences in single unit operations vs. automated platforms
  • The cost of manufacturing: what’s the cost of manual vs automated manufacturing models?
  • What does comparability look like and is it worth the time and cost? How long do you wait?
  • When do we move to automation?
  • What process translation looks like moving to an automated platform
  • How Lonza envisions manufacturing cell and gene therapies

The Lonza logo is a Lonza Ltd. Trademark

Matthew Hewitt
Matthew Hewitt
Head, R&D and Clinical Development, Personalized Medicine at

Matthew Hewitt is currently the Head of Clinical Development for the Personalized Medicine (PerMed) Initiative within Lonza. The PerMed Initiative has a cell and gene therapy focus working to alleviate pain-points in commercializing cell therapies. One of Matt’s responsibilities is the Cocoon Platform, a closed, automated, scalable cell therapy manufacturing platform which relieves many cell therapy manufacturing difficulties.

Prior to joining Lonza, Matt led the Tumor Immunology and Microenvironment program at Bellicum Pharmaceuticals which concentrated on improving cell therapy efficacy in solid tumors. Matt led the Immunology group at the University of Pennsylvania’s Gene Therapy Program under Dr. James Wilson managing numerous AAV gene therapy programs. Matt received his Ph.D. in Biophysics & Physiology from the University of Alabama at Birmingham and completed his post-doctoral fellowship at Johns Hopkins University.

Donna Rill
Donna Rill
Chief Technology Officer at Triumvira Immunologics Inc

Ms. Rill is currently serving as the Chief Technical Officer of Triumvira Immunologics, USA, Inc. She has extensive manufacturing, clinical and translational research laboratory experience in cell and gene therapy, monoclonal antibody production, and protein production. She has setup and managed core development laboratories covering a large range of testing services to facilitate research, core drug development activities as well as manufacturing and quality control laboratories. With her expertise in the areas of laboratory construction, project management, development and operations, cGMP, cGTP, and GLP regulatory compliance, quality control/assurance system, database development,  and clinical standards of practice, she has designed and qualified cGMP Cell & Gene Therapy Laboratories, cGMP Vector Production facilities, core service laboratories, and Translational Research Labs. 

Ms. Rill has previously held the positions of Vice President of Manufacturing for Cell Medica, Chief Development Officer for Opexa Therapeutics, Laboratory Director of Cell and Gene Therapy, Translational Research Laboratories for Cell and Gene Therapy, Baylor College of Medicine; Associate Scientist/Lab Manager of the Bone Marrow Transplant Research Laboratory, and the GMP Cell & Gene Therapy Laboratories, St. Jude Children’s Research Hospital; Education Coordinator and Clinical Instructor, Department of Clinical Laboratory, LeBonheur Children's Medical Center and University of Tennessee Center for the Health Sciences.